KRX Aesthetics PD-13 Therapy NDC 84755-0010

NDC codes

FDA NDC Directory

Product NDC (as listed)84755-0010Labeler and product segments. Claims need a package NDC.

Product NDC at billing width84755-0010Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
84755-0010-1	84755001001	15 mL in 1 PACKAGE (84755-0010-1)Marketed from Jan 1, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): KRX Aesthetics PD-13 Therapy
Generic name (nonproprietary): krx aesthetics pd-13 therapy
Active ingredients: Methyl aminolevulinate hydrochloride — 1.95 mg/15mL
Dosage form: Spray
Route: Topical
Labeler: KRX RESOURCES SDN. BHD.
Product type: Over-the-counter drug
Marketing category: Unapproved drug (other)
Marketing start: Jan 1, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Porphyrinogens (Chemical structure)
Identifiers: Product ID 84755-0010_4e6af886-2e2f-0343-e063-6394a90ad095SPL ID 4e6af886-2e2f-0343-e063-6394a90ad095SPL set ID 4e6af886-2e2e-0343-e063-6394a90ad095UNII 7S73606O1A
Pharmacologic class: Porphyrin Precursor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N484755001001 followed by a unit qualifier and the quantity

Package 84755-0010-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 1, 2026.

Indications (excerpt from the label)

Krx Aesthetics PD-13 Therapy, which includes 13% of Methyl Aminolevulinate HCI, is developed to maximize the client’s satisfaction for PDT(Photo Dynamic Therapy).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)